Latest Advances in Lung Cancer Research

Merck halted a lung cancer trial combining vibostolimab with Keytruda due to ineffectiveness and side effects. This setback highlights challenges in developing TIGIT inhibitors for cancer treatment.

Dato-DXd shows promise in treating advanced “HER2-low” lung cancer, slowing progression and potentially extending survival.

Study finds lung cancer patients show distinct lung microbiome profiles versus benign diseases. Analyzing microbial features in bronchoalveolar lavage fluid could serve as minimally invasive biomarker for lung cancer detection, reducing need for biopsies.

LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints. Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpression.

Experimental gene therapy drug HPN328 is being tested with Tecentriq in a trial to enhance immune response against small cell lung cancer.

This study assessed real-world survival among older patients with non–small-cell lung cancer (NSCLC) and brain metastases (BMs) at diagnosis receiving first-line immune checkpoint inhibitors (ICIs) compared with chemotherapy only.

A recent multicenter study published in The Lancet highlights the promising efficacy of immunotherapy in advanced lung cancer patients.

Rybrevant plus chemo extends progression-free survival for newly diagnosed EGFR exon 20 patients, per study in Journal of Clinical Oncology.

Bristol-Myers Squibb’s CheckMate-9LA trial shows combining nivolumab, ipilimumab, and chemotherapy improves outcomes in advanced NSCLC patients.

In a recent study, patients who took Keytruda before and after surgery had better results than those who only had surgery.

The phase 3 Pragmatica-Lung study has broader eligibility criteria than many other trials, expanding access to more patients and clinicians.

New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.